Clinical Trial

A Research Study of VCT220 in Adult Chinese Participants With Obesity

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-21.
Trial Details
NCT Number NCT06939296
Lead Sponsor Vincentage Pharma Co., Ltd
Conditions Obesity, Overweight
Enrollment 840 participants
Start Date 2024-12-24
Primary Completion 2025-11-25 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27